. 2019 Mar 29;17:102. doi: 10.1186/s12967-019-1851-1

Table 1.

Patient characteristics with respect to PCDH17 expression

Patient characteristics	AML (TCGA dataset)
Patient characteristics	High PCDH17 (n = 86)	Low PCDH17 (n = 87)	P
Age, years			0.41
Median	59	57
Range	18–88	21–82
Sex (male/female)	54/32	38/49	0.01
WBC count, × 10⁹/L			< 0.0001
Median	9.3	34
Range	0.4–116.2	0.8–297.4
BM blasts, %			0.04
Median	68.5	75
Range	30–100	32–100
PB blasts, %			< 0.001
Median	18	49
Range	0–97	0–98
Karyotype			0.343
Favorable	16	16
Intermediate	46	55
Adverse	23	14
Unknown	1	2
FLT3-ITD			0.002
Present	6	21
Absent	80	66
NPM1			0.02
Mutated	17	31
Wild-type	69	56
CEBPA			1
Single mutated	4	4
Double mutated	2	3
Wild-type	80	80
IDH1			0.28
Mutated	10	6
Wild-type	76	81
IDH2			0.82
Mutated	8	9
Wild-type	78	78
RUNX1			0.769
Mutated	8	7
Wild-type	78	80
DNMT3A			0.755
Mutated	20	22
Wild-type	66	65
TP53			0.005
Mutated	12	2
Wild-type	74	85
ERG expression^a			0.08
High	37	49
Low	49	38
BAALC expression^a			0.494
High	45	41
Low	41	46
MN1 expression^a			0.704
High	44	42
Low	42	45
WT1 expression^a			0.323
High	40	47
Low	46	40

AML acute myeloid leukemia, TCGA The Cancer Genome Atlas, WBC white blood cells, BM bone marrow, PB peripheral blood, ITD internal tandem duplication

^aThe median expression value was used as a cut point